The Gaucher Outcome Survey (GOS) is an international Gaucher disease (GD) registry established in 2010 for patients with a confirmed GD diagnosis, regardless of GD type or treatment status, designed to evaluate the safety and long-term effectiveness of velaglucerase alfa and other GD-related treatments. As of February 25, 2017, 1209 patients had enrolled, the majority from Israel (44.3%) and the US (31.4%). Median age at GOS entry was 40.4 years, 44.1% were male, and 13.3% had undergone a total splenectomy. Most patients had type 1 GD (91.5%) and were of Ashkenazi Jewish ethnicity (55.8%). N370S/N370S was the most prevalent genotype, accounting for 44.2% of genotype-confirmed individuals (n 5 847); however, there was considerable variation between countries. A total of 887 (73.4%) patients had received 1 GD-specific treatment at any time, most commonly imiglucerase (n 5 587), velaglucerase alfa (n 5 507), and alglucerase (n 5 102). Hematological and visceral findings at the time of GOS entry were close to normal for most patients, probably a result of previous treatment;
| I N TR ODU C TI ON
Gaucher disease (GD) is an autosomal recessive disease caused by pathogenic variations in the GBA1 gene, which encodes the lysosomal enzyme b-glucocerebrosidase, resulting in deficient activity of this enzyme. 1 GD affects approximately 1 in 40 000 individuals worldwide 1 and is characterized by glucocerebroside accumulation in lysosomes, resulting in disease manifestations primarily in the organs of the monocyte-macrophage system.
GD may be regarded as a phenotypic continuum 2 owing to its highly variable clinical presentation; however, patients continue to be classified into the traditionally recognized clinical variants of GD, types 1, 2, or 3, to facilitate patient management. Type 1, the nonneuronopathic form, is typically characterized by splenomegaly, hepatomegaly, thrombocytopenia, and anemia. 1 It is the most common form, estimated to affect 90% of diagnosed patients in Europe, North America, and Australia. 1 According to a recent literature analysis of individuals who manifest the disease, the prevalence ranges from 0.70 to 1.75 in 100 000. 3 There is a higher prevalence of type 1 GD among people of Ashkenazi Jewish ethnicity, with a birth incidence of about 1 in 850. 1 As with other rare diseases, the development of effective management strategies for GD may be hampered by an incomplete understanding of the natural history of the disease, as well as the challenge of conducting large, long-term, placebo-controlled clinical trials. Since 1991, the standard of care for GD has been enzyme replacement therapy (ERT), initially with placenta-derived alglucerase (now discontinued). 4 Although regulatory status and approved indications may differ between countries, ERTs available for GD include imiglucerase (Cerezyme®, Sanofi/Genzyme Corporation, USA), produced in Chinese hamster ovary cells and differing from the native human enzyme by a single amino acid substitution; 5, 6 taliglucerase alfa (Elelyso ® , Pfizer, USA/Protalix, Israel), produced in a carrot-cell system and having the same core amino acid sequence as the native human enzyme, differing by 2 and 7 amino acids at the N-terminus and C-terminus, respectively; 7-9 and velaglucerase alfa (VPRIV ® , Shire, USA), produced in a human cell line and having the same amino acid sequence as the human enzyme. 10 Substrate reduction therapy has also been available since 2002, and includes miglustat (Zavesca ® , Actelion, Switzerland) 11 and eliglustat (Cerdelga ® , Sanofi/Genzyme, USA). 12 The pharmacological chaperone ambroxol is also under investigation for the treatment of patients with both neuronopathic and non-neuronopathic forms of GD. 13, 14 Observational studies, including prospective long-term patient registries, can help to expand the knowledge base for rare diseases, allowing clinical information to be collected from larger, more heterogeneous populations than otherwise possible by clinical trials. This can help to better define the population distribution of the disease and its variability in presentation or severity, and assess response to treatment to inform management strategies. The Gaucher Outcome Survey (GOS)
is an international GD-specific registry established in 2010 for patients with a confirmed GD diagnosis, regardless of GD type or treatment status. The primary objectives of GOS are to evaluate the safety and longterm effectiveness of velaglucerase alfa and other GD-related treatments, to gain a better understanding of the natural history of GD, and to serve as a database for evidence-based management of GD.
Here we provide an overview of GOS and present the baseline demographic and general disease characteristics of participating patients in the registry. This analysis also provides a baseline for additional analyses and makes comparisons between specific subpopulations within GOS.
| M A TER I A LS A N D M ETH OD S
GOS is an ongoing registry designed to document the clinical outcome of patients with GD over time, with 31 active sites in 11 countries as of February 25, 2017 (Argentina, Brazil, France, Israel, Italy, Paraguay, Poland, Russia, Spain, the UK, and the US). The registry was initiated in September 2010 by Shire Human Genetic Therapies, Inc, in collaboration with leading international experts on GD, as part of postmarketing commitments to regulatory authorities. The management, administration, and infrastructure of GOS is funded by Shire. The specific aims of GOS are to better characterize the global GD population, to monitor the natural history of treated and untreated patients with GD of any type, and to enhance understanding of the effectiveness and safety of current GD treatments through observing the evolving nature of the disease among patients treated to varying degrees and at different stages. GOS is directed by a steering committee that includes international experts (investigators) and medical personnel from Shire.
The steering committee meets on an annual basis to review the progress in the operation, database management, and analysis of GOS.
| Patients
Patients with a diagnosis of GD of any type (based on enzymatic assay 
| Analysis
Analyses were conducted on patient baseline data (defined as at time of GOS entry) extracted from the database for all patients enrolled into GOS on February 25, 2017. All-patient analyses included all patients with available data for the chosen variable. For analyses of treatment status, treated patients were defined as those with one or more records of a GD-specific treatment and a treatment start date specified.
Untreated patients were defined as individuals for whom there was a recorded indication of not having received GD-specific therapy and no record of GD-specific treatment at any time. Patients not meeting the criteria for classification as "treated" or "untreated", that is, with no information on treatment status or treatment start date, were classified as "missing treatment status" and excluded from treatment status analyses. All analyses were regarded as exploratory. Countries with fewer than 100 patients enrolled in GOS are grouped in the "rest of world" (ROW) category, which includes Argentina, Brazil, Spain, France, Italy, Paraguay, Poland, and Russia.
Spleen and liver volumes were measured predominantly by 3D ultrasound in Israel, as well as a few sites elsewhere in the world, and were recalculated using an algorithm of conversion to be comparable to computed tomography (CT) measurements as previously described. 15 Briefly, estimated spleen CT 5 539.5 1 0.344 (spleen ultrasound volume) and estimated liver CT 5 320.86 1 0.317 (liver ultrasound volume), where ultrasound organ volume was calculated as the product of the 3 largest organ dimensions: longitudinal, transverse at maximal plane, and true anteroposterior.
| RE S U L TS

| Population demographics
A total of 1209 patients at 31 active sites in 11 countries had participated in the study as of February 25, 2017 . The majority of patients were from Israel (44.3%), the US (31.4%), and the UK (9.8%), with the remaining 14.5% from Poland, Brazil, Russia, Paraguay, France, Spain, Argentina, and Italy (Supporting information, Figure S1 ). Figure S2 ).
| Treatment status
A total of 887 (73.4%) of 1209 patients enrolled in GOS had received GD-specific treatments at any time, while 174 (14.4%) patients were untreated; treatment information was not available for 148 (12.2%) patients (Table 1 ; Figure 1 ). Of the treated patients, 843 (95.0%) had type 1 GD, 3 (0.3%) had type 2 GD, and 35 (3.9%) had type 3 GD (GD information missing for 6 patients) ( Figure 1 ). The most widely used GD-specific treatments were imiglucerase (n 5 587), velaglucerase alfa (n 5 507), alglucerase (n 5 102), taliglucerase alfa (n 5 93), and miglustat (n 5 91). Patients from the UK were more likely to be receiving GDspecific treatment at GOS entry (93.3% vs. 73.4% overall), while almost one-third (28.4%) of patients from Israel were untreated at GOS entry, compared with <5% of patients in the UK, US, and ROW (Table 1) .
Further analyses relating to treatment patterns in GD patients enrolled in GOS have been reported separately. 
| D I SCUSSION
GOS is an ongoing, global, GD-specific disease registry with >1200 patients included from 11 countries, with a preponderance ) and the prevalence of the N370S allele among the Ashkenazi Jewish population. 20 The majority (58.9%) of patients in Israel were N370S homozygous, consistent with a milder phenotype, 21 In contrast to findings from the ICGG registry, in which most patients had low hemoglobin and platelet levels and enlarged liver and spleen volumes, 18 hematological and visceral findings at the time of GOS entry were close to normal for the majority of patients, probably An important consideration is the abdominal imaging methodologies utilized in GOS. Abdominal imaging was performed using magnetic resonance imaging (MRI)/CT in most participating countries, whereas 3D ultrasound was used in Israel (and a few other sites), with results converted to estimated MRI/CT values using the calculation published by Elstein et al. 15 Although this calculation has been used previously with ICGG registry data, 18, [23] [24] [25] spleen sizes stratified by country have not previously been reported. Other methodologies for conversion of 3D ultrasound to MRI/CT values are available; for example, a calculation published by Yetter et al. 26 When applied to these data, the latter calcu- vs. 6.5 MN), which might be in part related to the lower dose of ERT used in this country. 16 These findings suggest that the enlarged spleen sizes in Israeli patients may reflect genuine differences from other countries, rather than being a result of differing imaging modalities, and warrants further investigation.
Registries can provide a valuable source of real-world data for rare conditions like GD, where data collection from clinical trials would be challenging. However, evaluation of registry data has several limitations.
Owing to the nature of participation in GOS (at the discretion of patients and their treating physicians), data input is reliant on the choice and subsequent declaration of the participating physician; data may therefore be incomplete, missing, based on broad criteria, or subject to selection bias, particularly in the reporting of treated patients over untreated patients.
A few sites initially enrolled only treated patients or those who had been . Treated at any time: patients who had one or more records of a GD-specific treatment and a treatment start date specified. Untreated: patients for whom there was a recorded indication of not having received GD-specific treatment and no indication of GD-specific treatment at any time. Missing information: patients who were missing information on treatment status or treatment start date. GD, Gaucher disease; GOS, Gaucher Outcome Survey treatment-specific registries for GD, and some sites may not be able to enroll all patients into all registries for which they are eligible.
As an ongoing registry, the structure and design of GOS is evolving in order to reflect the changing demographic characteristics of the GD population and to present data on relevant clinical outcomes. Previous analyses of GOS data have evaluated trends in treatment patterns 16 and the impact of treatment during pregnancy, 27 while ongoing analyses will examine patient comorbidities, skeletal abnormalities, patients with type 3 GD, and outcomes with long-term treatment.
In conclusion, the findings from this evaluation of baseline data provide insights into the key demographic and disease characteristics of patients with GD who are enrolled in GOS and, together with future evaluations, will help to improve understanding of the natural history of the disease and the overall management of patients with GD. 
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